This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Metagenomics of the Human Intestinal Tract | |
|---|---|
| Name | Metagenomics of the Human Intestinal Tract |
| Field | Microbiology; Genomics; Bioinformatics |
| Established | 2000s |
| Notable people | Craig Venter; J. Craig Venter; Rob Knight; Jeffrey Gordon; R. Reid |
| Institutions | National Institutes of Health; Wellcome Trust; Broad Institute |
Metagenomics of the Human Intestinal Tract Metagenomics of the Human Intestinal Tract examines microbial communities in the Human gastrointestinal tract, integrating methods from DNA sequencing, bioinformatics, microbiology, and systems biology to profile taxonomy and function, and informing research by consortia such as the Human Microbiome Project, the MetaHIT consortium, and the Broad Institute projects. Studies link discoveries by investigators like Jeffrey Gordon, Rob Knight, and J. Craig Venter to clinical initiatives at the National Institutes of Health, the Wellcome Trust, and biotechnology firms collaborating with the European Molecular Biology Laboratory and the Max Planck Society.
Metagenomics of the Human Intestinal Tract emerged through collaborations among researchers at the National Institutes of Health, the Sanger Institute, and the Broad Institute, building on concepts promoted by Carl Woese and technologies pioneered by Kary Mullis and J. Craig Venter, and accelerated by funding from the Wellcome Trust and initiatives like the Human Microbiome Project. Early landmark publications from teams led by Jeffrey Gordon and consortia such as MetaHIT and laboratories at the European Molecular Biology Laboratory reframed perspectives on health guided by translational partnerships with hospitals like Mayo Clinic and research centers at Harvard University and Stanford University. The field synthesizes contributions from investigators including Rob Knight, Ruth Ley, and George Weinstock and relies on platforms developed by companies like Illumina and institutions such as the Broad Institute and the Wellcome Sanger Institute.
Sampling protocols reference cohort studies from centers including the Massachusetts General Hospital, the Johns Hopkins Hospital, and the Karolinska Institute, and employ collection approaches standardized by consortia like the Human Microbiome Project and the MetaHIT project. Sequencing strategies use instruments from Illumina, Pacific Biosciences, and Oxford Nanopore Technologies, adopting workflows influenced by scientists such as Katherine Pollard and George Weinstock, and leveraging library preparations developed in laboratories at the Broad Institute and the Wellcome Sanger Institute. Laboratory teams often coordinate with biobanks like the UK Biobank and clinical networks at the National Institutes of Health and the European Molecular Biology Laboratory to integrate metadata standards recommended by the World Health Organization and regulatory frameworks informed by agencies such as the Food and Drug Administration.
Analytical pipelines draw on tools and resources from groups led by Rob Knight, Peer Bork, and Eric Alm, using software originally developed at institutions like the University of California, San Diego and the Max Planck Society, and databases maintained by the National Center for Biotechnology Information and the European Nucleotide Archive. Taxonomic profiling uses approaches inspired by work from Terry Speed and Sarah Teichmann, while functional annotation leverages catalogs generated by the Human Microbiome Project and the MetaHIT consortium, integrating reference genomes from the Broad Institute and the Wellcome Sanger Institute. Statistical frameworks adapt methods from researchers at Stanford University, Harvard University, and the University of Oxford to control batch effects noted in multicenter studies coordinated by the National Institutes of Health and funded by the Wellcome Trust.
Characterization of community composition references discoveries by Jeffrey Gordon, Ruth Ley, and Rob Knight, documenting dominant bacterial taxa including representatives analogous to taxa described in studies at the Sanger Institute, the Broad Institute, and the European Molecular Biology Laboratory, and noting functional repertoires cataloged by the MetaHIT project and the Human Microbiome Project. Functional profiling highlights metabolic pathways contextualized with known pathways curated by the Kyoto University groups and resources from the European Bioinformatics Institute and institutions such as the Max Planck Society, linking microbial genes to host nutritional interactions investigated at the Wageningen University and clinical cohorts from the Mayo Clinic and Johns Hopkins Hospital.
Research teams including Jeffrey Gordon, Ruth Ley, and Bert Vogelstein have associated microbial community states with conditions studied at centers like the Massachusetts General Hospital, the University of Washington, and the Karolinska Institute, implicating microbiome shifts in disorders addressed in trials at the National Institutes of Health and hospitals such as the Cleveland Clinic. Mechanistic studies reference immunology groups at the Dana-Farber Cancer Institute and metabolic research at Harvard Medical School, while translational efforts engage companies and institutions such as Seres Therapeutics and the Broad Institute to explore microbiome impacts on therapies studied in consortia like the Human Microbiome Project.
Clinical translation builds on fecal microbiota transplantation programs at hospitals including the Mayo Clinic and research partnerships with firms like Seres Therapeutics and platforms developed at the Broad Institute, supported by regulatory oversight from the Food and Drug Administration and collaborative networks including the National Institutes of Health. Diagnostic and therapeutic pipelines reference commercialization efforts by companies such as Enterome and Second Genome, and clinical trials registered through institutions like the National Institutes of Health and conducted at academic centers including Johns Hopkins Hospital and the Massachusetts General Hospital.
Limitations discussed by consortia such as MetaHIT and the Human Microbiome Project include sample heterogeneity noted by investigators at the Wellcome Sanger Institute and computational reproducibility concerns addressed by groups at Stanford University, Harvard University, and the University of California, San Diego, while future directions emphasize integrative studies coordinated by institutions like the Broad Institute, the Max Planck Society, and the European Molecular Biology Laboratory to translate insights into interventions piloted at the National Institutes of Health and in partnerships with industry leaders such as Illumina and Oxford Nanopore Technologies.